
## **Claus Lindbjerg Andersen**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5939718/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets. Cancer Research, 2004, 64, 5245-5250.	0.4	5,993
2	Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature, 2006, 444, 633-637.	13.7	1,777
3	Direct detection of early-stage cancers using circulating tumor DNA. Science Translational Medicine, 2017, 9, .	5.8	808
4	Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 2019, 570, 385-389.	13.7	764
5	Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncology, 2019, 5, 1124.	3.4	538
6	Diagnostic and Prognostic MicroRNAs in Stage II Colon Cancer. Cancer Research, 2008, 68, 6416-6424.	0.4	459
7	A Dual Program for Translation Regulation in Cellular Proliferation and Differentiation. Cell, 2014, 158, 1281-1292.	13.5	414
8	An Optimized Shotgun Strategy for the Rapid Generation of Comprehensive Human Proteomes. Cell Systems, 2017, 4, 587-599.e4.	2.9	413
9	p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest. Cancer Research, 2008, 68, 10094-10104.	0.4	412
10	Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clinical Cancer Research, 2009, 15, 7642-7651.	3.2	395
11	Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut, 2016, 65, 625-634.	6.1	381
12	Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death <i>In vitro</i> . Cancer Research, 2009, 69, 4851-4860.	0.4	349
13	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. Journal of Clinical Oncology, 2019, 37, 1547-1557.	0.8	298
14	Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue. PLoS ONE, 2014, 9, e98187.	1.1	284
15	Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. Clinical Cancer Research, 2017, 23, 5437-5445.	3.2	232
16	Alternative Splicing in Colon, Bladder, and Prostate Cancer Identified by Exon Array Analysis. Molecular and Cellular Proteomics, 2008, 7, 1214-1224.	2.5	202
17	Dynamics of human DNA topoisomerases IlÎ $\pm$ and IlÎ $^2$ in living cells. Journal of Cell Biology, 2002, 157, 31-44.	2.3	190
18	SNHG5 promotes colorectal cancer cell survival by counteracting STAU1-mediated mRNA destabilization. Nature Communications, 2016, 7, 13875.	5.8	170

#	Article	IF	CITATIONS
19	Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nature Communications, 2021, 12, 5060.	5.8	161
20	SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Molecular Oncology, 2016, 10, 1266-1282.	2.1	151
21	Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. International Journal of Cancer, 2011, 129, 2855-2866.	2.3	140
22	Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics, 2011, 12, 435.	1.2	140
23	Putative cis-regulatory drivers in colorectal cancer. Nature, 2014, 512, 87-90.	13.7	136
24	Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. International Journal of Cancer, 2013, 132, E48-57.	2.3	126
25	The splicing factor <scp>SRSF6</scp> is amplified and is an oncoprotein inÂlung and colon cancers. Journal of Pathology, 2013, 229, 630-639.	2.1	126
26	Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells. British Journal of Cancer, 2011, 105, 552-561.	2.9	106
27	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. Clinical Cancer Research, 2022, 28, 507-517.	3.2	104
28	Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis, 2007, 28, 38-48.	1.3	97
29	Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. British Journal of Cancer, 2009, 100, 511-523.	2.9	94
30	A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Nature Communications, 2014, 5, 3608.	5.8	94
31	Mnk2 Alternative Splicing Modulates the p38-MAPK Pathway and Impacts Ras-Induced Transformation. Cell Reports, 2014, 7, 501-513.	2.9	92
32	MiRNAâ€362â€3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer. International Journal of Cancer, 2013, 133, 67-78.	2.3	91
33	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. Molecular Oncology, 2015, 9, 1169-1185.	2.1	91
34	The effect of surgical trauma on circulating free DNA levels in cancer patients—implications for studies of circulating tumor DNA. Molecular Oncology, 2020, 14, 1670-1679.	2.1	89
35	miRNA profiling of circulating EpCAM <sup>+</sup> extracellular vesicles: promising biomarkers of colorectal cancer. Journal of Extracellular Vesicles, 2016, 5, 31488.	5.5	88
36	Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors. Clinical Cancer Research, 2005, 11, 7709-7719.	3.2	87

#	Article	IF	CITATIONS
37	DNA Copy-Number Alterations Underlie Gene Expression Differences between Microsatellite Stable and Unstable Colorectal Cancers. Clinical Cancer Research, 2008, 14, 8061-8069.	3.2	84
38	Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer—a clinical biomarker discovery and validation study. Clinical Epigenetics, 2019, 11, 158.	1.8	83
39	miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells. Nature Communications, 2016, 7, 12436.	5.8	82
40	Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer. Cell Reports, 2017, 19, 1268-1280.	2.9	79
41	Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene, 2012, 31, 4409-4419.	2.6	77
42	High expression of microRNAâ€625â€3p is associated with poor response to firstâ€line oxaliplatin based treatment of metastatic colorectal cancer. Molecular Oncology, 2013, 7, 637-646.	2.1	77
43	Alternative Splicing of SLC39A14 in Colorectal Cancer is Regulated by the Wnt Pathway. Molecular and Cellular Proteomics, 2011, 10, M110.002998.	2.5	73
44	Gene expression signatures for colorectal cancer microsatellite status and HNPCC. British Journal of Cancer, 2005, 92, 2240-2248.	2.9	70
45	Nonâ€CpG island promoter hypomethylation and miRâ€149 regulate the expression of <i>SRPX2</i> in colorectal cancer. International Journal of Cancer, 2013, 132, 2303-2315.	2.3	68
46	High-Throughput Copy Number Analysis of 17q23 in 3520 Tissue Specimens by Fluorescence in Situ Hybridization to Tissue Microarrays. American Journal of Pathology, 2002, 161, 73-79.	1.9	66
47	Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene, 2012, 31, 2750-2760.	2.6	66
48	Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups. British Journal of Cancer, 2007, 96, 1896-1903.	2.9	65
49	Clusterin Expression in Normal Mucosa and Colorectal Cancer. Molecular and Cellular Proteomics, 2007, 6, 1039-1048.	2.5	61
50	Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry, 2001, 45, 83-86.	1.8	60
51	Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis. BMC Genomics, 2011, 12, 505.	1.2	57
52	The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death and Differentiation, 2013, 20, 1485-1497.	5.0	57
53	Comparative analysis of 12 different kits for bisulfite conversion of circulating cell-free DNA. Epigenetics, 2017, 12, 626-636.	1.3	56
54	Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. European Journal of Heart Failure, 2009, 11, 638-647.	2.9	53

#	Article	IF	CITATIONS
55	Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array. British Journal of Cancer, 2007, 96, 499-506.	2.9	50
56	Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer. PLoS ONE, 2014, 9, e96767.	1.1	49
57	Characterization of genetic intratumor heterogeneity in colorectal cancer and matching patientâ€derived spheroid cultures. Molecular Oncology, 2018, 12, 132-147.	2.1	49
58	The non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction and promotes colorectal cancer progression. Nature Communications, 2017, 8, 14418.	5.8	48
59	Are microRNAs located in genomic regions associated with cancer?. British Journal of Cancer, 2006, 95, 1415-1418.	2.9	42
60	Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia. Haematologica, 2002, 87, 357-62.	1.7	42
61	Frequent genomic loss at chr16p13.2 is associated with poor prognosis in colorectal cancer. International Journal of Cancer, 2011, 129, 1848-1858.	2.3	41
62	DAPK1 loss triggers tumor invasion in colorectal tumor cells. Cell Death and Disease, 2019, 10, 895.	2.7	41
63	Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case–control study. BMC Cancer, 2015, 15, 819.	1.1	39
64	Clusterin expression can be modulated by changes in TCF1-mediated Wnt signaling. Journal of Molecular Signaling, 2007, 2, 6.	0.5	36
65	A narrow deletion of 7q is common to HCL, and SMZL, but not CLL. European Journal of Haematology, 2004, 72, 390-402.	1.1	35
66	A genetically inducible porcine model of intestinal cancer. Molecular Oncology, 2017, 11, 1616-1629.	2.1	34
67	Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study. European Journal of Cancer, 2022, 163, 163-176.	1.3	33
68	Identification of 33 candidate oncogenes by screening for base-specific mutations. British Journal of Cancer, 2014, 111, 1657-1662.	2.9	30
69	Active, but not inactive, human centromeres display topoisomerase II activity in vivo. Chromosome Research, 2002, 10, 305-312.	1.0	29
70	Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2005, 156, 122-128.	1.0	26
71	CpG islands detected by self-primed in situ labeling (SPRINS). Chromosoma, 1998, 107, 260-266.	1.0	25
72	A Hidden Markov Model to estimate population mixture and allelic copy-numbers in cancers using Affymetrix SNP arrays. BMC Bioinformatics, 2007, 8, 434.	1.2	25

#	Article	IF	CITATIONS
73	Contribution of allelic imbalance to colorectal cancer. Nature Communications, 2018, 9, 3664.	5.8	25
74	Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. Scientific Reports, 2019, 9, 11542.	1.6	25
75	Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. Oncology Letters, 2011, 2, 1101-1106.	0.8	24
76	IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer – intervention trial 2. Study protocol. Acta Oncológica, 2020, 59, 336-341.	0.8	24
77	Circulating tumor <scp>DNA</scp> for prognosis assessment and postoperative management after curativeâ€intent resection of colorectal liver metastases. International Journal of Cancer, 2022, 150, 1537-1548.	2.3	22
78	Determinants of recurrence after intended curative resection for colorectal cancer. Scandinavian Journal of Gastroenterology, 2014, 49, 1399-1408.	0.6	18
79	Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients. BMC Cancer, 2019, 19, 971.	1.1	18
80	Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients Journal of Clinical Oncology, 2021, 39, 11-11.	0.8	18
81	Genotyping and annotation of Affymetrix SNP arrays. Nucleic Acids Research, 2006, 34, e100-e100.	6.5	17
82	The association between genetic variants in hMLH1 and hMSH2 and the development of sporadic colorectal cancer in the Danish population. BMC Medical Genetics, 2008, 9, 52.	2.1	14
83	Development of blood-based biomarker tests for early detection of colorectal neoplasia: Influence of blood collection timing and handling procedures. Clinica Chimica Acta, 2020, 507, 39-53.	0.5	14
84	The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer. BMC Genomics, 2015, 16, 404.	1.2	13
85	Transcriptomic and proteomic intra-tumor heterogeneity of colorectal cancer varies depending on tumor location within the colorectum. PLoS ONE, 2020, 15, e0241148.	1.1	13
86	Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion. Clinical Chemistry, 2020, 66, 925-933.	1.5	12
87	A Beta-mixture model for dimensionality reduction, sample classification and analysis. BMC Bioinformatics, 2011, 12, 215.	1.2	10
88	Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC Journal of Clinical Oncology, 2020, 38, 4009-4009.	0.8	10
89	Triage for selection to colonoscopy?. European Journal of Surgical Oncology, 2018, 44, 1539-1541.	0.5	9
90	Ageâ€stratified reference intervals unlock the clinical potential of circulating cellâ€free <scp>DNA</scp> as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer. International Journal of Cancer, 2021, 148, 1665-1675.	2.3	9

#	Article	IF	CITATIONS
91	Error Characterization and Statistical Modeling Improves Circulating Tumor DNA Detection by Droplet Digital PCR. Clinical Chemistry, 2022, 68, 657-667.	1.5	9
92	Trisomy 10 Survival: A Literature Review and Presentation of Seven New Cases. Cancer Genetics and Cytogenetics, 1998, 103, 130-132.	1.0	8
93	Characterization of three hairy cell leukemia- derived cell lines (ESKOL, JOK-1, and Hair-M) by multiplex-FISH, comparative genomic hybridization, FISH, PRINS, and dideoxyPRINS. Cytogenetic and Genome Research, 2000, 90, 30-39.	0.6	8
94	Functional characterization of rare missense mutations in MLH1 and MSH2 identified in Danish colorectal cancer patients. Familial Cancer, 2009, 8, 489-500.	0.9	8
95	Recurrent imbalances involving chromosome 5 and 7q22-q35 in hairy cell leukemia: A comparative genomic hybridization study. Genes Chromosomes and Cancer, 2001, 30, 218-219.	1.5	7
96	Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 6082.	1.8	7
97	The Monosomy 7 Clone in Interphase and Metaphase Cell Populations: A Combined Chromosome and Primed in situ Labeling Study. Acta Haematologica, 1997, 97, 216-221.	0.7	6
98	Putting a brake on stress signaling:miR-625-3pas a biomarker for choice of therapy in colorectal cancer. Epigenomics, 2016, 8, 1449-1452.	1.0	6
99	Rseg—an R package to optimize segmentation of SNP array data. Bioinformatics, 2011, 27, 419-420.	1.8	5
100	MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer. Nature Communications, 2020, 11, 2025.	5.8	5
101	Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients Journal of Clinical Oncology, 2021, 39, 3540-3540.	0.8	5
102	Extensive cytogenetic analysis of a stable dicentric isochromosome 21, idic(21), formed by fusion of the terminal long arms. Cytogenetic and Genome Research, 2002, 97, 145-148.	0.6	3
103	SNPTools: a software tool for visualization and analysis of microarray data. Bioinformatics, 2007, 23, 1550-1552.	1.8	3
104	Early detection of lung cancer using cfDNA fragmentation Journal of Clinical Oncology, 2021, 39, 8519-8519.	0.8	3
105	DNA Microarrays and Genetic Testing. , 2010, , 247-265.		2
106	3′-UTR poly(T/U) repeat of EWSR1 is altered in microsatellite unstable colorectal cancer with nearly perfect sensitivity. Familial Cancer, 2015, 14, 449-453.	0.9	2
107	Abstract LB-476: A universal method for elimination of haemolyzed plasma samples that improves miRNA signature performance for early detection of colorectal cancer. Cancer Research, 2012, 72, LB-476-LB-476.	0.4	2
108	Abstract 3964: In colorectal cancer cells, the beta-catenin/TCF complex regulates several growth suppressive microRNAs that target cancer promoting genes. , 2011, , .		1

#	Article	IF	CITATIONS
109	Abstract 4138: miRNA-362-3p is associated with recurrence of colorectal cancer and targets E2F1, USF2 and PTPN1. , 2012, , .		1
110	Abstract 4678: KIAA1199 depletion targets the wnt/beta catenin signaling pathway and impairs migration and proliferation of human colon cancer cells. , 2010, , .		1
111	Abstract 5193: Novel candidate oncogenes with mutation hot spots in microsatellite unstable colorectal cancer. , 2014, , .		1
112	Genome-wide cell-free DNA fragmentation profiling for early cancer detection Journal of Clinical Oncology, 2019, 37, 3018-3018.	0.8	1
113	Are CIMP and chr16p13.2 copyâ€number status independent prognostic markers in Stages II and III colorectal cancer?. International Journal of Cancer, 2012, 130, 243-243.	2.3	Ο
114	MethCORR infers gene expression from DNA methylation and allows molecular analysis of ten common cancer types using fresh-frozen and formalin-fixed paraffin-embedded tumor samples. Clinical Epigenetics, 2021, 13, 20.	1.8	0
115	Abstract 2853: Transposon-activated POU5F1B promotes colorectal cancer growth and metastasis. , 2021, , .		Ο
116	Methods for derivation of LOH and allelic copy numbers using SNP arrays. , 2009, , 52-77.		0
117	Abstract 2139: Loss at chr16p13.2 is frequently observed in colorectal neoplasia and is associated with poor prognosis. , 2010, , .		Ο
118	Abstract LB-68: Comparative analysis of the miRNome in tumors and plasma from colorectal cancer patients. , 2010, , .		0
119	Abstract 2816: Discovery of a miRNA-based RT-qPCR signature able to detect early stage colorectal cancer in blood plasma. , 2011, , .		Ο
120	Validation of a plasma-based miRNA PCR test for early detection of colorectal cancer Journal of Clinical Oncology, 2012, 30, 424-424.	0.8	0
121	Abstract 4701: Cancer-specific genomic rearrangements used to quantify disease burden in plasma from patients with colorectal cancer , 2013, , .		Ο
122	Abstract 5233: MicroRNA in biofluid as robust biomarkers for cancer. , 2014, , .		0
123	Abstract 2927: miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cell. , 2016, , .		Ο
124	Abstract 2630: Integration of tumor microenvironment and molecular subclassification of colorectal cancer identifies patient subsets with poor prognosis. , 2016, , .		0
125	Abstract 3804: Comprehensive comparison of bisulfite conversion kits: A guide for optimal sensitivity and specificity of circulating cell-free DNA methylation-based biomarkers. , 2017, , .		0
126	Abstract 2906: Characterization of genetic intratumor heterogeneity of colorectal cancer and matching organoids. , 2017, , .		0

#	Article	IF	CITATIONS
127	Plasma-only ctDNA-Guided MRD Detection in Patients with CRC—Letter. Clinical Cancer Research, 2021, 27, 6613-6613.	3.2	0
128	Title is missing!. , 2020, 15, e0241148.		0
129	Title is missing!. , 2020, 15, e0241148.		0
130	Title is missing!. , 2020, 15, e0241148.		0
131	Title is missing!. , 2020, 15, e0241148.		0